Adds a once-daily, oral therapy candidate for eosinophilic esophagitis with FDA Orphan Drug and Fast Track Designations –– ABO-801 acquired for ...

Multi-cohort Phase 1b study evaluating NTR-1011, a first-in-class DNASE1L3 fusion protein designed to degrade Neutrophil Extracellular Traps ...

U.S. children and adolescents see thousands of food marketing messages on digital media platforms each year, according to new ...

The State Department announced a $20 million reward for information on Iran's nuclear facilities, equipment and personnel.

The summit created a space for local food producers to explore collaboration in formal or informal ways.

Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported third-quarter 2026 financial results and provided an update on the commercial launch of ZEVASKYN. “Maximizing the opportunity for ZEVASKYN ...

Abeona Therapeutics acquires ABO-801, a once-daily oral therapy for eosinophilic esophagitis, from Ellodi in a deal worth up ...

Abeona Therapeutics Inc. announced the acquisition of APT-1011 (now ABO-801), a product candidate for eosinophilic esophagitis (EoE), from Ellodi Pharmaceuticals, and entered into a securities ...

Abeona Therapeutics Inc. ( ABEO) has acquired APT-1011, now renamed ABO-801, a Phase 3-ready drug candidate for eosinophilic esophagitis, while also securing $30 million in private financing to ...

The Miami Trace Panthers have put together one of the most memorable seasons in program history, but another significant ...

U.S. children and adolescents see thousands of food marketing messages on digital media platforms each year, according to new research published in ...

Operator: Good morning, everyone, and welcome to Abeona Therapeutics 3Q 2026 Conference Call. [Operator Instructions] Please ...